Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal graft-versus-host disease.

Andrulis M, Dietrich S, Longerich T, Koschny R, Burian M, Schmitt-Gräf A, Schirmacher P, Ho AD, Dreger P, Luft T.

Haematologica. 2012 Nov;97(11):1674-7. doi: 10.3324/haematol.2011.061051. Epub 2012 Jun 11.

2.

Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system.

Luft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A, Neumann F, Isermann B, Hegenbart U, Ho AD, Dreger P.

Blood. 2011 Aug 11;118(6):1685-92. doi: 10.1182/blood-2011-02-334821. Epub 2011 Jun 2.

3.

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.

MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, Davies SM, Blazar BR.

Biol Blood Marrow Transplant. 2002;8(7):387-94.

PMID:
12171485
4.

High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy.

Dietrich S, Okun JG, Schmidt K, Falk CS, Wagner AH, Karamustafa S, Radujkovic A, Hegenbart U, Ho AD, Dreger P, Luft T.

Haematologica. 2014 Mar;99(3):541-7. doi: 10.3324/haematol.2013.090209. Epub 2013 Oct 18.

5.

Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment.

Dietrich S, Falk CS, Benner A, Karamustafa S, Hahn E, Andrulis M, Hegenbart U, Ho AD, Dreger P, Luft T.

Biol Blood Marrow Transplant. 2013 Jan;19(1):22-7. doi: 10.1016/j.bbmt.2012.09.018. Epub 2012 Oct 3.

7.

Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease.

Salat C, Holler E, Kolb HJ, Pihusch R, Reinhardt B, Hiller E.

Bone Marrow Transplant. 1997 May;19(9):909-14.

8.

Gastrointestinal pathology of autologous graft-versus-host disease following hematopoietic stem cell transplantation: a clinicopathological study of 17 cases.

Cogbill CH, Drobyski WR, Komorowski RA.

Mod Pathol. 2011 Jan;24(1):117-25. doi: 10.1038/modpathol.2010.163. Epub 2010 Oct 15.

9.

Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study.

Herrmann R, Sturm M, Shaw K, Purtill D, Cooney J, Wright M, Phillips M, Cannell P.

Int J Hematol. 2012 Feb;95(2):182-8. doi: 10.1007/s12185-011-0989-2. Epub 2011 Dec 20.

PMID:
22183779
10.

Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.

Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT.

Leukemia. 2003 May;17(5):841-8. Review.

PMID:
12750695
11.

Intra-arterial steroid-injection therapy for steroid-refractory acute graft-versus-host disease with the evaluation of angiography.

Nakai K, Tajima K, Tanigawa N, Matsumoto N, Zen K, Nomura S, Fujimoto M, Kishimoto Y, Amakawa R, Sawada S, Fukuhara S.

Bone Marrow Transplant. 2004 Jun;33(12):1231-3.

PMID:
15094752
12.

Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.

Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D, Donohue T, Shalabi R, Carvallo C, Barrett AJ, Geller N, Childs R.

Br J Haematol. 2004 Mar;124(6):777-86.

PMID:
15009066
13.

Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease.

Melson J, Jakate S, Fung H, Arai S, Keshavarzian A.

Am J Hematol. 2007 Oct;82(10):881-6.

14.

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.

Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J.

Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83.

15.

Persistence of recipient-type endothelium after allogeneic hematopoietic stem cell transplantation.

Mueller RJ, Stussi G, Puga Yung G, Nikolic M, Soldini D, Halter J, Meyer-Monard S, Gratwohl A, Passweg JR, Odermatt B, Schanz U, Biedermann BC, Seebach JD.

Haematologica. 2011 Jan;96(1):119-27. doi: 10.3324/haematol.2010.030288. Epub 2010 Oct 7.

16.

Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin.

Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R, Westervelt P, Trinkaus K, Goodnough LT, Hayashi RJ, Parker P, Forman SJ, DiPersio JF.

Bone Marrow Transplant. 2001 May;27(10):1059-64.

17.

Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease.

Gutiérrez-Aguirre CH, Cantú-Rodríguez OG, Borjas-Almaguer OD, González-Llano O, Jaime-Pérez JC, Solano-Genesta M, Gómez-Guijosa M, Mancias-Guerra C, Tarin L, Gómez-Almaguer D.

Haematologica. 2012 May;97(5):717-22. doi: 10.3324/haematol.2011.054577. Epub 2011 Dec 1.

18.

Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation.

Min CK, Kim DW, Lee JW, Min WS, Kim CC.

Acta Haematol. 2000;104(4):185-92.

PMID:
11279309
19.

A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.

Conrad R, Remberger M, Cederlund K, Ringdén O, Barkholt L.

Haematologica. 2008 Feb;93(2):265-72. doi: 10.3324/haematol.11672.

20.

Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.

Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.

Haematologica. 2002 Jan;87(1):52-8.

Supplemental Content

Support Center